SERAGEN, INC. STOCK PURCHASE AGREEMENTStock Purchase Agreement • April 16th, 1997 • Lilly Eli & Co • Pharmaceutical preparations • Massachusetts
by and amongAgreement and Plan of Merger • December 1st, 2003 • Lilly Eli & Co • Pharmaceutical preparations • Delaware
UNDERWRITING AGREEMENTUnderwriting Agreement • July 12th, 2001 • Lilly Eli & Co • Pharmaceutical preparations
CONFORMED COPY STOCK PURCHASE AGREEMENTStock Purchase Agreement • February 8th, 1999 • Lilly Eli & Co • Pharmaceutical preparations • New York
STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (the "Agreement") is made as of the ___ day of _____________, 1997 (the "Effective Date"), by and between Ligand Pharmaceuticals Incorporated, a Delaware corporation (the "Company"), and Eli Lilly...Stock Purchase Agreement • December 5th, 1997 • Lilly Eli & Co • Pharmaceutical preparations • Delaware
AMENDMENT NO. 1 TO RIGHTS AGREEMENT This Amendment No. 1 to Rights Agreement ("Amendment") is dated as of May 27, 2003, between Eli Lilly and Company, an Indiana corporation (the "Company") and Wells Fargo Bank Minnesota, N.A., a national banking...Rights Agreement • May 30th, 2003 • Lilly Eli & Co • Pharmaceutical preparations • Indiana
AndRights Agreement • March 15th, 2004 • Lilly Eli & Co • Pharmaceutical preparations • Indiana
AndRights Agreement • July 23rd, 1998 • Lilly Eli & Co • Pharmaceutical preparations • Indiana
OPTION AND WHOLESALE PURCHASE AGREEMENTStock Purchase Agreement • December 5th, 1997 • Lilly Eli & Co • Pharmaceutical preparations • Indiana
VOTING AGREEMENT VOTING AGREEMENT (the "Agreement"), dated as of February 23, 1998, between Eli Lilly and Company, an Indiana corporation (the "Stockholder"), and Baxter International Inc., a Delaware corporation ("Baxter"). WHEREAS, Baxter, RHB1...Voting Agreement • March 2nd, 1998 • Lilly Eli & Co • Pharmaceutical preparations • Delaware
ELI LILLY AND COMPANYLilly Eli & Co • January 10th, 1996 • Pharmaceutical preparations
May 11, 1998 Ligand Pharmaceuticals Incorporated 10275 Science Center Drive San Diego, CA 92121 Ladies and Gentlemen: The undersigned is a stockholder of Seragen, Inc., a Delaware corporation ("Seragen"). The undersigned understands that Seragen,...Lilly Eli & Co • May 22nd, 1998 • Pharmaceutical preparations
The undersigned is a stockholder of Seragen, Inc., a Delaware corporation ("Seragen"). The undersigned understands that Seragen, Ligand Pharmaceuticals Incorporated, a Delaware corporation ("Ligand"), and Knight Acquisition Corporation, a Delaware Corporation ("Merger Sub"), have entered into an Agreement and Plan of Reorganization, dated as of May 11, 1998 (the "Reorganization Agreement"), which provides for the merger (the "Merger") of Merger Sub into Seragen. The undersigned also understands that Ligand, at its option, may provide some or all of the Merger Consideration (as defined in the Reorganization Agreemnt) in the form of shares of voting common stock, par value $.001 per share, of Ligand (the "Common Stock"). The undersigned further understands that the issuance of the Common Stock pursuant to the terms of the Merger will be the subject of a registration statement under the Securities Act of 1933, as amended (the "Registration Statement"), which will be filed with the Securit
Eli Lilly and Company Relative Value Award Agreement (for Executive Officers)ELI LILLY & Co • February 21st, 2024 • Pharmaceutical preparations
This Relative Value Award has been granted on [•] (“Grant Date”) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (“Lilly” or the “Company”), to the Eligible Individual who has received this Relative Value Award Agreement (the “Grantee”).
ELI LILLY AND COMPANY Underwriting AgreementUnderwriting Agreement • February 9th, 2024 • ELI LILLY & Co • Pharmaceutical preparations
AMENDMENT NO. 3 TO OPTION AND WHOLESALE PURCHASE AGREEMENT This Amendment is executed as of the 11th day of May, 1998 by and between Eli Lilly and Company ("Lilly") and Ligand Pharmaceuticals Incorporated ("Ligand"). WHEREAS, Lilly and Ligand have...Option and Wholesale Purchase Agreement • May 22nd, 1998 • Lilly Eli & Co • Pharmaceutical preparations
TENDER AND SUPPORT AGREEMENTTender and Support Agreement • October 10th, 2008 • Lilly Eli & Co • Pharmaceutical preparations • Delaware
This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of October 6, 2008, is entered into by and among the entities listed on Schedule I hereto (each, a “Stockholder”) and Eli Lilly and Company, an Indiana corporation (“Parent”).
W I T N E S S E T H:Voting and Support Agreement • December 1st, 2003 • Lilly Eli & Co • Pharmaceutical preparations • Delaware
TENDER AND SUPPORT AGREEMENTTender and Support Agreement • July 7th, 2023 • ELI LILLY & Co • Pharmaceutical preparations • Delaware
This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of June 28, 2023, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Shenandoah Acquisition Corporation, a Delaware corporation and a direct wholly-owned subsidiary of Parent (“Purchaser”), and one or more stockholders of Sigilon Therapeutics, Inc., a Delaware corporation (the “Company”), set forth on Schedule A hereto (each, a “Stockholder” and, if applicable, collectively, the “Stockholders”). All terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).
SHARE ISSUANCE AGREEMENTShare Issuance Agreement • December 20th, 2018 • Lilly Eli & Co • Pharmaceutical preparations • Delaware
AGREEMENT AND PLAN OF MERGER Among ELI LILLY AND COMPANY, ALASKA ACQUISITION CORPORATION and IMCLONE SYSTEMS INCORPORATED Dated as of October 6, 2008Agreement and Plan of Merger • October 10th, 2008 • Lilly Eli & Co • Pharmaceutical preparations • Delaware
The Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred upon the stockholders herein are granted subject to this reservation.
Eli Lilly and Company Restricted Stock Unit Award Agreement (for Executive Officer)Restricted Stock Unit Award Agreement • February 21st, 2024 • ELI LILLY & Co • Pharmaceutical preparations
This Restricted Stock Unit Award has been granted on [•] (“Grant Date”) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (“Lilly” or the “Company”), to the Eligible Individual who has received this Restricted Stock Unit Award Agreement (the “Grantee”).
Eli Lilly and Company Performance Award AgreementPerformance Award Agreement • February 23rd, 2022 • ELI LILLY & Co • Pharmaceutical preparations
This Performance Award has been granted on [•] (“Grant Date”) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (“Lilly” or the “Company”), to the Eligible Individual who has received this Performance Award Agreement (the “Grantee”).
Eli Lilly and Company Performance Award Agreement (for Executive Officers)ELI LILLY & Co • February 23rd, 2022 • Pharmaceutical preparations
This Performance Award has been granted on [•] (“Grant Date”) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (“Lilly” or the “Company”), to the Eligible Individual who has received this Performance Award Agreement (the “Grantee”).
STOCK AND ASSET PURCHASE AGREEMENT between NOVARTIS AG and ELI LILLY AND COMPANYStock and Asset Purchase Agreement • July 28th, 2014 • Lilly Eli & Co • Pharmaceutical preparations • New York
THIS STOCK AND ASSET PURCHASE AGREEMENT (as it may be amended or supplemented from time to time in accordance with the terms hereof, this Agreement), dated as of April 22, 2014, is entered into by and between Novartis AG, a company incorporated under the laws of Switzerland (the Seller), and Eli Lilly and Company, a corporation organized under the laws of Indiana (the Purchaser; each of the Purchaser and the Seller is a Party and together are the Parties).
Name] [Address] [Address] Re: Non-Compete Payment Agreement Dear [Name]:Payment Agreement • February 22nd, 2023 • ELI LILLY & Co • Pharmaceutical preparations • Indiana
This sets forth the terms of the Non-Compete Payment Agreement (the “Agreement”) between [name] (“Executive”) and Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (“Lilly” or the “Company”), regarding Executive’s post-employment restrictive covenants.
CONFIDENTIAL MASTER SETTLEMENT AGREEMENTConfidential Master Settlement Agreement • November 3rd, 2005 • Lilly Eli & Co • Pharmaceutical preparations • Indiana
FIRST AMENDMENT TO STOCK AND ASSET PURCHASE AGREEMENTStock and Asset Purchase Agreement • February 19th, 2015 • Lilly Eli & Co • Pharmaceutical preparations
This First Amendment to the Stock and Asset Purchase Agreement (this Amendment Agreement) dated as of December 17, 2014, is entered into by and between Novartis AG, a company incorporated under the laws of Switzerland (the Seller), and Eli Lilly and Company, a corporation organized under the laws of Indiana (the Purchaser, each of the Purchaser and the Seller is a Party and together are the Parties).
ARMO BIOSCIENCES, INC.Non-Disclosure Agreement • May 23rd, 2018 • Lilly Eli & Co • Pharmaceutical preparations
Bluegill Acquisition Corporation, a Delaware corporation (“Purchaser”) and wholly-owned subsidiary of Eli Lilly and Company, an Indiana corporation (“Lilly”), is offering to purchase all outstanding shares of common stock, par value, $0.0001 per share (the “Shares”), of ARMO BioSciences, Inc., a Delaware corporation (“ARMO”), at a purchase price of $50.00 per Share (the “Offer Price”), net to the seller in cash, without interest and less any applicable tax withholding, upon the terms and subject to the conditions set forth in this Offer to Purchase and in the related Letter of Transmittal (which, together with this Offer to Purchase, as they may be amended or supplemented from time to time, collectively constitute the “Offer”).
Joint Filing AgreementJoint Filing Agreement • December 22nd, 2020 • ELI LILLY & Co • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.0001 per share, of Prevail Therapeutics Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement this 22nd day of December, 2020.
Joint Filing AgreementJoint Filing Agreement • January 15th, 2019 • Lilly Eli & Co • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.0001 per share, of Loxo Oncology, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement this 15th day of January, 2019.
CONFIDENTIAL MASTER SETTLEMENT AGREEMENTConfidential Master Settlement Agreement • August 4th, 2006 • Lilly Eli & Co • Pharmaceutical preparations • Indiana
TRIPARTITE AGREEMENT UNSECURED DEBTTripartite Agreement • February 27th, 2009 • Lilly Eli & Co • Pharmaceutical preparations • New York
WHEREAS, the Issuer and Citibank entered into a certain Indenture dated as of February I, 1991, as amended and supplemented (the “Indenture’) with respect to the issuance from time to time of the following debt securities (collectively, the “Securities”):
Underwriting AgreementUnderwriting Agreement • March 14th, 2007 • Lilly Eli & Co • Pharmaceutical preparations • New York
Eli Lilly and Company, an Indiana corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), $1,000,000,000 principal amount of its 5.20% Notes due 2017 (the “2017 Notes”), $700,000,000 principal amount of its 5.50% Notes due 2027 (the “2027 Notes”) and $800,000,000 principal amount of its 5.55% Notes due 2037 (the “2037 Notes”), in each case having the terms set forth in Schedule 2 hereto (such 2017 Notes, 2027 Notes and 2037 Notes collectively, the “Securities”). The Securities will be issued pursuant to an Indenture dated as of February 1, 1991 (as may be supplemented from time to time, the “Indenture”) between the Company and Citibank, N.A., as trustee (the “Trustee”).
Eli Lilly and Company Performance Award Agreement (for Executive Officers)ELI LILLY & Co • November 1st, 2022 • Pharmaceutical preparations
This Performance Award has been granted on [•] (“Grant Date”) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (“Lilly” or the “Company”), to the Eligible Individual who has received this Performance Award Agreement (the “Grantee”).
FORM OF RESTATED AND AMENDED INDEMNITY AGREEMENTIndemnity Agreement • December 22nd, 2003 • Lilly Eli & Co • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT, effective as of , between Applied Molecular Evolution, Inc., a Delaware corporation (the “Corporation”), and (the “Indemnitee”),
